SB 4425, the “No Immunity for Glyphosate Act,” would bar the use of federal funds to implement Executive Order 14387, which concerns ensuring an adequate supply of elemental phosphorus and glyphosate-based herbicides for national defense purposes. In practical terms, the bill would block federal implementation, administration, or enforcement of that executive order. It is framed as a direct response to federal support for the production and supply chain of these chemicals.
The bill also creates a broad federal cause of action for people who claim physical injury, illness, disease, or death from exposure to elemental phosphorus or glyphosate-based herbicides. It allows suits in federal court against manufacturers, distributors, formulators, suppliers, contractors, subcontractors, and other covered entities, and authorizes compensatory damages, punitive damages, injunctive relief, declaratory relief, and attorney’s fees. The measure expressly removes immunity defenses, including defenses based on the Defense Production Act, federal contractor immunity, preemption, or compliance with federal authorization, and it preserves existing and pending claims while making clear that state-law remedies are not displaced.
The bill’s impact on state and federal law would be significant for product-liability and toxic-tort litigation involving glyphosate and elemental phosphorus. It would expand access to federal courts, override certain federal immunity and preemption defenses, and preserve parallel state-law claims and remedies. It would also affect companies involved in the manufacture, distribution, sale, or supply of these substances by exposing them to broader civil liability.
There is no recorded committee transcript or vote history provided, so no formal debate or roll-call sentiment is available. Based on the bill text and sponsors, the measure appears strongly critical of federal support for glyphosate-related production and of legal protections for covered entities, while emphasizing consumer and public-health accountability. The title and structure suggest a policy dispute over balancing national-defense supply needs against environmental and health concerns tied to glyphosate exposure.
The main point of contention is likely the bill’s elimination of immunity and preemption defenses for entities acting under federal authority, which could be viewed by supporters as necessary accountability and by opponents as undermining defense-related supply chains and exposing contractors to expansive litigation. Another likely controversy is the bill’s retroactive application to claims arising before enactment, which could affect pending and past disputes.
SB 4425 would preclude federal spending to carry out Executive Order 14387 and would create a new federal civil-liability framework for claims involving elemental phosphorus and glyphosate-based herbicides. It would expand potential liability for manufacturers, distributors, suppliers, contractors, and subcontractors, while expressly preserving state-law causes of action and remedies and limiting the availability of federal immunity, contractor-defense, and preemption arguments.
No committee discussion or votes are provided, so there is no recorded legislative sentiment from hearings or floor action. From the bill’s text and sponsorship, the measure appears to be driven by concern over health harms and legal accountability, and to be opposed in principle to federal support or legal shielding for glyphosate-related production. The overall tone is adversarial toward the executive order and protective of injured claimants.
The central controversy is whether Congress should block federal implementation of a national-defense-related executive order and strip immunity defenses from entities producing or supplying elemental phosphorus and glyphosate-based herbicides. Supporters would likely argue the bill restores accountability for alleged injuries and preserves state remedies, while opponents would likely argue it interferes with defense supply policy, disrupts federal contracting, and invites broad litigation. The retroactive reach of the bill and its explicit rejection of federal contractor immunity are also likely to be disputed.